JP2019523779A - 抗マラリア組成物およびその使用 - Google Patents

抗マラリア組成物およびその使用 Download PDF

Info

Publication number
JP2019523779A
JP2019523779A JP2018566499A JP2018566499A JP2019523779A JP 2019523779 A JP2019523779 A JP 2019523779A JP 2018566499 A JP2018566499 A JP 2018566499A JP 2018566499 A JP2018566499 A JP 2018566499A JP 2019523779 A JP2019523779 A JP 2019523779A
Authority
JP
Japan
Prior art keywords
formula
compound
alkyl
compounds
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018566499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523779A5 (https=
Inventor
アンダージー，ウィル・ジョセフ
チャタジー，アーナブ・ケー
マクナマラ，ケース・ダブリュー
ビーズリー，フェデリーコ・シー
エリアセン，アンダース・マイケル
パトラッシ，ハンク・マイケル・ジェームズ
ローランド，ジェイソン・ティー
ウェルス，ティモシー
ザトリチナヤ，オリガ・ウラジミロヴナ
ジョウ，フェイ
シュルツ，ペーター・ジー
Original Assignee
ザ スクリプス リサーチ インスティテュート
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート, ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2019523779A publication Critical patent/JP2019523779A/ja
Publication of JP2019523779A5 publication Critical patent/JP2019523779A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/65—Halogen-containing esters of unsaturated acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018566499A 2016-06-20 2017-06-19 抗マラリア組成物およびその使用 Pending JP2019523779A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662352455P 2016-06-20 2016-06-20
US62/352,455 2016-06-20
PCT/US2017/038173 WO2017222996A1 (en) 2016-06-20 2017-06-19 Antimalarial compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2019523779A true JP2019523779A (ja) 2019-08-29
JP2019523779A5 JP2019523779A5 (https=) 2020-04-16

Family

ID=60784061

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018566499A Pending JP2019523779A (ja) 2016-06-20 2017-06-19 抗マラリア組成物およびその使用

Country Status (12)

Country Link
US (3) US10947176B2 (https=)
EP (1) EP3471711A4 (https=)
JP (1) JP2019523779A (https=)
KR (1) KR20190020774A (https=)
CN (2) CN109715147A (https=)
AU (1) AU2017281426B2 (https=)
BR (1) BR112018076619A2 (https=)
CA (1) CA3028392A1 (https=)
EA (1) EA201990064A1 (https=)
MA (1) MA45411A (https=)
SG (2) SG11201811434RA (https=)
WO (1) WO2017222996A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201990064A1 (ru) * 2016-06-20 2019-05-31 Дзе Скриппс Рисерч Инститьют Противомалярийные композиции и варианты их применения
WO2020051130A1 (en) * 2018-09-04 2020-03-12 President And Fellows Of Harvard College Method for reducing parasite burden in a mosquito
BR112022022984A2 (pt) * 2020-05-11 2022-12-20 Univ Oregon Health & Science Intermediários e síntese para compostos de quinolona do tipo endoquina
WO2022144920A1 (en) * 2020-12-30 2022-07-07 Ipca Laboratories Limited Atovaquone prodrugs
WO2025151263A1 (en) * 2024-01-09 2025-07-17 Sri International Oil-based compositions and methods of making and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0291037A (ja) * 1988-08-16 1990-03-30 Wellcome Found Ltd:The 治療剤
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
JPH11504339A (ja) * 1995-05-01 1999-04-20 スコシア ホールディングス ピーエルシー 生物活性化合物としての脂肪酸エステル
JP2010526131A (ja) * 2007-05-09 2010-07-29 ラボラトリオ キミコ インテルナツィオナーレ ソチエタ ペル アツィオーニ トランス−２，３−二置換ナフトキノンの製法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819477D0 (en) * 1988-08-16 1988-09-21 Wellcome Found Medicaments
US5206268A (en) * 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
GB9207517D0 (en) 1992-04-06 1992-05-20 Wellcome Found Heterocyclic compounds
EA201990064A1 (ru) * 2016-06-20 2019-05-31 Дзе Скриппс Рисерч Инститьют Противомалярийные композиции и варианты их применения

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0291037A (ja) * 1988-08-16 1990-03-30 Wellcome Found Ltd:The 治療剤
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
JPH11504339A (ja) * 1995-05-01 1999-04-20 スコシア ホールディングス ピーエルシー 生物活性化合物としての脂肪酸エステル
JP2010526131A (ja) * 2007-05-09 2010-07-29 ラボラトリオ キミコ インテルナツィオナーレ ソチエタ ペル アツィオーニ トランス−２，３−二置換ナフトキノンの製法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 44(11), JPN6021000787, 2009, pages 4778 - 4782, ISSN: 0004543795 *
THE APPS JOURNAL, vol. 11(4), JPN6021000789, 2009, pages 762 - 770, ISSN: 0004425063 *

Also Published As

Publication number Publication date
AU2017281426A1 (en) 2019-01-17
KR20190020774A (ko) 2019-03-04
CA3028392A1 (en) 2017-12-28
WO2017222996A1 (en) 2017-12-28
AU2017281426B2 (en) 2021-10-14
CN109715147A (zh) 2019-05-03
EP3471711A1 (en) 2019-04-24
EA201990064A1 (ru) 2019-05-31
SG10202112759SA (en) 2021-12-30
MA45411A (fr) 2019-04-24
US20190202766A1 (en) 2019-07-04
BR112018076619A2 (pt) 2019-04-02
US20210179524A1 (en) 2021-06-17
US11485697B2 (en) 2022-11-01
US10947176B2 (en) 2021-03-16
US20230111793A1 (en) 2023-04-13
SG11201811434RA (en) 2019-01-30
EP3471711A4 (en) 2020-02-19
CN114569552A (zh) 2022-06-03

Similar Documents

Publication Publication Date Title
CN103781783B (zh) 作为抗精神病药物的哌嗪取代的苯并噻吩衍生物
JP2019523779A (ja) 抗マラリア組成物およびその使用
AU2017242867B9 (en) Vortioxetine pamoic acid salt and crystal form thereof
WO2017015360A1 (en) Quinolone-3-diarylethers
SK141898A3 (en) Substituted tetracyclic tetrahydrofuran derivatives
KR20140099492A (ko) 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도
JP2021035991A (ja) 医薬
JP2024523881A (ja) 薬学的化合物
OA19130A (en) Antimalarial compositions and uses thereof
CA3238235A1 (en) Pyrazine compounds useful in the treatment of parasitic protozoal infection
WO2023239811A1 (en) Substituted biaryl endochin-like quinolones with enhanced antiparasitic activity
WO2024258904A1 (en) Tetrahydroacridinone analogues for treatment and prevention of malaria
TW201717950A (zh) 用於治療疾病的雜芳基碳化腈
JPH0859616A (ja) α−（４−クロロフェニル）−４−［（４−フルオロフェニル）メチル］ピペリジン−１−エタノールエステル類、その製造法及び治療上の応用
Šůs Synthesis of precursors of 4-quinolones against Trypanosoma brucei for 18F-radiolabelling

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211105

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211105

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211124

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220111

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220118

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220204

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220208

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230124

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230322

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230425